Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genetic Analysis AS's Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.18 Mil. Therefore, Genetic Analysis AS's EV-to-EBIT ratio for today is -3.37.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Genetic Analysis AS's Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.10 Mil. Therefore, Genetic Analysis AS's EV-to-EBITDA ratio for today is -6.72.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Genetic Analysis AS's Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr18.16 Mil. Therefore, Genetic Analysis AS's EV-to-Revenue ratio for today is 1.89.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Genetic Analysis AS (XSAT:GEAN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.18 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.10 Mil.
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.16 Mil.
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.05 Mil.
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil.
Genetic Analysis AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS Enterprise Value Related Terms
Genetic Analysis AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:GEAN vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Genetic Analysis AS's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (XSAT:GEAN) has a Enterprise Value of kr34.29 Mil as of Jul. 19, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Genetic Analysis AS and its competitors.
Is Genetic Analysis AS's Enterprise Value too high?
Genetic Analysis AS's current Enterprise Value is kr34.29 Mil. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Enterprise Value compare to TMO and DHR?
Genetic Analysis AS's Enterprise Value of kr34.29 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current Enterprise Value is kr34.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current Enterprise Value is kr34.29 Mil. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Enterprise Value is kr34.29 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54.
GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.
Key valuation signals for XSAT:GEAN:
Enterprise Value: kr34.29 Mil
GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for XSAT:GEAN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:GEAN has been successfully added to your 
